Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441870 · ClinicalTrials.gov registry record · Phase 1
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors
A Phase 1 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT00441870: Completed Phase 1 study, sponsored by Endocyte.
NCT00441870 is a Phase 1 study that has completed, run by Endocyte. The registered enrollment target is 77 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00441870, a Phase 1 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0225 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.
Interventions
- DRUG EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)
- DRUG 99mTC-EC20 (Folic acid-technetium 99m conjugate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
What the finished NCT00441870 record still lists
NCT00441870 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% higher).
The record links to 0 conditions, and to 2 interventions - of which EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate) is the first listed.
NCT00441870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00441870 about?
NCT00441870 is a clinical study titled "Study of EC0225 for the Treatment of Refractory or Metastatic Tumors". This is a Phase 1 clinical trial evaluating the safety and tolerability of escalating doses of EC0225 in patients with refractory or metastatic tumors who have exhausted standard therapeutic options.
What is the current status of trial NCT00441870?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2007-02. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00441870?
The interventions under investigation include: EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate) (DRUG), 99mTC-EC20 (Folic acid-technetium 99m conjugate) (DRUG).
Who is sponsoring clinical trial NCT00441870?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00441870's enrollment target sits among peer trials
77 703rd of 2000 higher than 1,296 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia